In general, the mutation profile was broadly similar between AITL and PTCL‐TFH, with the most frequent mutation being TET2 (72%, 73% respectively), followed by RHOA (61%, 45% respectively) and DNMT3A (34%, 36% respectively) (Figure 1). This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.